Search
Can Fite Biopharma Ltd
CANFAdd to Watchlist
4.700USD
+1.730+58.25%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
41.02KMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+58.25%
5 Days
+57.19%
1 Month
+45.06%
6 Months
+17.50%
Year to Date
+17.50%
1 Year
+351.92%
Key Figures
5.000Open
5.980High
57.50MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
658753.92%Turnover Ratio
2.970Prev. Close
3.820Low
167.07MTurnover
LossP/E Static
0.01P/B
0.00%Div Yield TTM
-105.48%ROA
36.40052wk High
11.13Volume Ratio
-7.88MNet Profit
8.73KShares
-1791.0240EPS TTM
1.09Beta
-178.24%ROE
2.95052wk Low
72.73%Amplitude
100.00%Gross Margin
41.02KMarket Cap
-0.81Reward/Risk
5.55%Risk Rate
TradingKey Stock Score of Can Fite Biopharma Ltd
Currency: USD Updated: 2026-06-30Key Insights
Can Fite Biopharma Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Growing
The company is in a growing phase, with the latest annual income totaling USD 405.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 405.00K.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.13K shares, decreasing 71.76% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
50.000
Target Price
+1583.50%
Upside Space
Can Fite Biopharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Can Fite Biopharma Ltd Info
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Ticker SymbolCANF
CompanyCan Fite Biopharma Ltd
CEOFishman (Pnina)
Websitehttps://www.canfite.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52281.700
+27.400 (+0.05%)
29933.000
+133.700 (+0.45%)
7492.900
+17.400 (+0.23%)
15221.000
-134.000 (-0.87%)
69461.000
-24.000 (-0.04%)
6290.400
+15.000 (+0.24%)
67.574
-0.394 (-0.58%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4052.230
+21.460 (+0.53%)
FAQs
What is the current price of Can Fite Biopharma Ltd (CANF)?
The current price of Can Fite Biopharma Ltd (CANF) is 4.70.
What is the symbol of Can Fite Biopharma Ltd?
The ticker symbol of Can Fite Biopharma Ltd is CANF.
What is the 52-week high of Can Fite Biopharma Ltd?
The 52-week high of Can Fite Biopharma Ltd is 36.40.
What is the 52-week low of Can Fite Biopharma Ltd?
The 52-week low of Can Fite Biopharma Ltd is 2.95.
What is the market capitalization of Can Fite Biopharma Ltd?
The market capitalization of Can Fite Biopharma Ltd is 41.02K.
Is Can Fite Biopharma Ltd (CANF) currently rated as Buy, Hold, or Sell?
According to analysts, Can Fite Biopharma Ltd (CANF) has an overall rating of Buy, with a price target of 50.00.
What is the Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF)?
The Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF) is -1791.02.